For the year ending 2025-12-31, WHWK had $8,834K increase in cash & cash equivalents over the period. -$97,985K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -20,596 |
| Share-based compensation expense | 9,873 |
| Gain on sale of business | 87,266 |
| Amortization of premiums and discounts on short-term investments, net | 1,527 |
| Non-cash lease expense | 74 |
| Depreciation and amortization expense | 79 |
| Accounts receivable | 1,000 |
| Inventory | -170 |
| Prepaid expenses and other current assets | 434 |
| Other non-current assets | 438 |
| Operating lease liabilities, net | -89 |
| Accounts payable and accrued liabilities | 3,923 |
| Other liabilities | -202 |
| Net cash used in operating activities | -97,433 |
| Proceeds from sale of business, net cash, cash equivalents, and restricted cash | 101,286 |
| Purchases of property and equipment | 552 |
| Purchases of short-term investments | 148,688 |
| Maturities of short-term investments | 59,845 |
| Net cash provided by investing activities | 11,891 |
| Proceeds from sale of common stock and prefunded warrants in pipe financing | 100,002 |
| Payment of pipe financing related transaction costs | 5,625 |
| Issuance of common stock upon exercise of stock options | 26 |
| Proceeds from issuance under employee stock purchase plan | 49 |
| Deferred offering costs paid for financing | 76 |
| Net cash provided by financing activities | 94,376 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 8,834 |
| Cash, cash equivalents and restricted cash at beginning of year | 28,734 |
| Cash, cash equivalents and restricted cash at end of year | 37,568 |
Whitehawk Therapeutics, Inc. (WHWK)
Whitehawk Therapeutics, Inc. (WHWK)